Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 5/20 | 0.68 |
| ▸ | TACR1 | P25103 | 5/20 | 0.51 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.49 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8864168 | 0.91 | CHRNA7 (0.58) | CHRNA7TACR1SLC18A3CHRNB2CHRNA4 | |
| SCHEMBL8863923 | 0.87 | CHRNA7 (0.58) | CHRNA7TACR1SLC18A3CHRNB2CHRNA4 | |
| SCHEMBL701302 | 0.82 | CHRNA7 (1.00) | CHRNA7CHRNB2CHRNA4 | |
| SCHEMBL699884 | 0.82 | CHRNA7 (1.00) | CHRNA7CHRNB2CHRNA4 | |
| SCHEMBL699598 | 0.82 | CHRNA7 (1.00) | CHRNA7CHRNB2CHRNA4 | |
| SCHEMBL8863987 | 0.80 | CHRNA7 (0.53) | CHRNA7CHRNB2CHRNA4 | |
| SCHEMBL6012064 | 0.79 | CHRNA7 (0.68) | CHRNA7TACR1SLC18A3CHRNB2CHRNA4 | |
| SCHEMBL7668602 | 0.75 | CHRNA7 (0.85) | CHRNA7CHRNB2CHRNA4 | |
| SCHEMBL28838840 | 0.75 | CHRNA7 (0.62) | CHRNA7CHRNB2CHRNA4 | |
| Methane SCHEMBL9464123 | 0.74 | TACR1 (0.47) | CHRNA7TACR1SLC18A3CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7687630-B2 | Method for producing optically active quinuclidinols having one or more substituted groups at the 2-position | KANTO KAGAKU KABUSHIKI KAISHA (JP) | 2010-03-30 | — | — | US | disclosed |
| US-20080081911-A1 | Method for producing optically active quinuclidinols having one or more substituted groups at the 2-position | KANTO KAGAKU KABUSHIKI KAISHA (JP) | 2008-04-03 | — | — | US | disclosed |
| EP-1389208-B1 | SUBSTITUTED AZABICYCLIC MOIETIES FOR THE TREATMENT OF DISEASE (NICOTINIC ACETHYLCHOLINE RECEPTOR AGONISTS) | PHARMACIA & UPJOHN CO LLC (US) | 2005-12-28 | — | — | EP | disclosed |
| US-6869946-B2 | Substituted azabicyclic moieties for the treatment of disease | PFIZER INC (US) | 2005-03-22 | — | — | US | disclosed |
| EP-1389208-A1 | SUBSTITUTED AZABICYCLIC MOIETIES FOR THE TREATMENT OF DISEASE (NICOTINIC ACETHYLCHOLINE RECEPTOR ANTAGONISTS) | PHARMACIA & UPJOHN COMPANY (US) | 2004-02-18 | — | — | EP | disclosed |
| US-20030055043-A1 | Substituted azabicyclic moieties for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-03-20 | — | — | US | disclosed |
| WO-2002085901-A1 | SUBSTITUTED AZABICYCLIC MOIETIES FOR THE TREATMENT OF DISEASE (NICOTINIC ACETHYLCHOLINE RECEPTOR AGONISTS) | PHARMACIA & UPJOHN COMPANY (US) | 2002-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080081911-A1 | Method for producing optically active quinuclidinols having one or more substituted groups at the 2-position | NQO1, SQLE, NQO2 | CHRNA7 2512/4885TACR1 2370/4885SLC18A3 1260/4885 |
| US-20030055043-A1 | Substituted azabicyclic moieties for the treatment of disease | CHRNA1, CHRNA7, CHRNA5 | CHRNA7 2/4885TACR1 256/4885SLC18A3 419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.